联邦制药附属公司头孢噻肟钠通过仿制药一致性评价
4月15日，联邦制药（03933）发布公告，宣布其全资附属公司珠海联邦制药股份有限公司中山分公司申报的注射用头孢噻肟钠（规格：1.0g；2.0g）已获得中国国家药品监督管理局的批准，成功通过仿制药质量和疗效一致性评价。
注射用头孢噻肟钠作为第三代头孢菌素类抗生素，具有广泛的临床应用，适用于治疗多种感染，包括下呼吸道感染和泌尿生殖道感染等。
此次获批将进一步巩固公司在抗感染领域的优势地位，并预计将为公司及其股东创造更大的收益。公司表示将持续致力于新产品研发及推进一致性评价，以提升市场竞争力和财务表现。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10